Ironwood Pharmaceuticals (IRWD) has risen sharply, recording gains of 7.13% in the past 4 weeks. However, the stock has corrected -0.98% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 3.64% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 4.69% and the 50-Day Moving Average is 9.41%. Ironwood Pharmaceuticals, Inc. is up 35.22% in the last 3-month period. Year-to-Date the stock performance stands at 21.92%.
Ironwood Pharmaceuticals (NASDAQ:IRWD): On Fridays trading session , Opening price of the stock was $14.29 with an intraday high of $14.61. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $13.93. However, the stock managed to close at $14.13, a loss of 1.46% for the day. On the previous day, the stock had closed at $14.34. The total traded volume of the day was 1,399,101 shares.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.